Trial Profile
DD-723 Phase II clinical trial - Dose-response study in patients with suspected prostate cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Jun 2018
Price :
$35
*
At a glance
- Drugs Perflubutane (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
- 27 May 2016 New trial record